On Tuesday, Shares of New Residential Investment Corp. (NYSE:NRZ), loss -3.03% to $16.67.
New Residential Investment, declared that it will release its first quarter financial results for the period ended March 31, 2015 on Friday, May 8, 2015 preceding to the opening of the New York Stock Exchange.
In addition, administration will host a conference call on Friday, May 8, 2015 at 8:30 A.M. Eastern Time.
New Residential Investment Corp., a real estate investment trust (REIT), focuses on investing in and managing residential mortgage related assets. It operates through Servicing Related Assets, Residential Securities and Loans, and Other Investments segments.
Shares of Corning Inc. (NYSE:GLW), declined -2.99% to $20.80, during its last trading session.
The Board of Directors of Corning Incorporated, declared a quarterly dividend on the company`s common stock of $0.12 per share, payable on June 30, 2015, to holders of record on May 29, 2015.
Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials worldwide. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences.
At the end of Tuesday’s trade, Shares of StemCells Inc. (NASDAQ:STEM), dipped -2.97% to $0.59.
StemCells, offered a business update and stated financial results for the first quarter 2015.
“StemCells, Inc. continues to make great progress,” said Martin McGlynn, CEO of StemCells, Inc. “We have accomplished the enrollment of the first cohort in our Phase II Pathway StudyTM in cervical spinal cord injury. This cohort set medical history by successfully transplanting more neural stem cells into the human spinal cord than has ever been done formerly. Based on the timing of concluding cohort 1, we would expect to have interim six month results from this open label cohort accessible in the fourth quarter 2015. We will also be releasing top-line data from both of our Phase I/II studies shortly. Data from our thoracic spinal cord injury study will be released at the 4th ISCoS/ASIA Joint Scientific Meeting in May. Data from our dry age related macular degeneration study will be released in June at the 2015 ISSCR Annual Meeting.”
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development.
Finally, Vulcan Materials Company (NYSE:VMC), ended its last trade with -2.95% loss, and closed at $85.50.
Vulcan Materials Company, declared results for the first quarter ending March 31, 2015.
First Quarter Summary (contrast with preceding year’s first quarter)
- Total revenues raised $57 million, or 10 percent, to $631 million
- Total gross profit raised $44 million, or 128 percent, to $78 million
- Aggregates freight-adjusted revenues raised $56 million, or 17 percent, to $380 million
- Shipments raised 13 percent, or 3.9 million tons, to 33.5 million tons
- Same-store shipments raised 9 percent, or 2.7 million tons
- Segment gross profit raised $29 million, or 76 percent, to $68 million
- Incremental gross profit as a percent of freight-adjusted revenues was 52 percent
- On a same-store basis, this metric was 68 percent
- Average freight-adjusted sales price raised 4 percent despite negative product mix
- Asphalt, Concrete and Calcium segment gross profit improved $15 million, collectively
- SAG was flat over the preceding year, at about $67 million
- Adjusted EBITDA was $77 million, an enhance of $38 million, or 97 percent.
Vulcan Materials Company produces and sells construction aggregates, asphalt mix, and ready-mixed concrete primarily in the United States. It operates through four segments: Aggregates, Asphalt Mix, Concrete, and Calcium.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
